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Abstract 
Introduction: Oral cancer is one of the causes of major morbidity and mortality in the world although incidence 
varies in the different geographical locations and races. Advances in molecular biology and cancer research have 
allowed elucidating serum biomarkers to improve diagnostic methods.  The aim of this article systematic review is 
to highlight the utility and clinical value of serum biomarkers in the diagnosis and prognosis of oral cancer.
Material and Methods: A systematic literature review using PubMed (MEDLINE databases) revealed a total of 140 
articles related to this topic. Of those articles, 29 were included in the final review. We included articles published in 
English in the last five years, developed in human as cases and controls studies, retrospective or prospective studies 
and specific studies that analyzed a certain biomarker in serum. 
Results: All of the studies include in this systematic review found significant differences in patients. Of those arti-
cles included, 2 used biomarkers to determinate cancerous phenotype, 11 mentioned their results were associated 
with worse prognosis and overall survival, 4 correlated biomarker concentration to clinical stages, 4 concluded it 
could be a helpful in diagnosis and 8 studies did not find a clear utility of the analysed biomarker. Due to differences 
in the presentation of data, meta-analysis was not possible. 
Conclusions: Biomarker use for diagnosis and prognosis is supported by clinical and scientific evidence is relevant. 
Nevertheless, after selecting a certain biomarker, monitoring protocols should be established in oral and maxillofa-
cial surgeons teams so as we have a correct understanding of biological values.
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Introduction
Oral cancer is the sixth most common malignancy 
worldwide. Aproximately, 90% of cancer located in the 
oral cavity are oral squamous cell carcinoma (OSCC) 
(1). Most oral cancers are superficial and easily detected, 
but deeply located tumors may not be noted until they 
have grown large and reached an advanced stage. This 
malignant neoplasm occurs most commonly in the pos-
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teriorlateral border and ventral surfaces of the tongue. 
The second most common location is the floor of the 
mouth (2). Due their aggressiveness, oral cancer inva-
des surrounding organs and causes regional or distant 
metastases (3). The overall survival rate for oral cancer 
is considerably lower than that of other cancers due to 
metastasis and recurrence (4). 
Epidemiological studies showed variable incidences de-
pending on the region. Incidence is particularly high in 
India, Brazil, Pakistan and France. Tobacco (particularly 
chewing) and alcohol have been large demonstrated as 
risk factors in the development of oral cancer (5). Addi-
tionally, these risk factors have been showed a synergist 
effect when they have been combined (6).
The determination of serum biomarkers is accepted as 
a valuable tool for diagnosis, finding therapeutic targets 
and prognosis in different kind of tumors (7). Literature 
has been showed overexpression in serum of some pro-
teins (8), p53 antibody (9), and VEGF (8) as an indicator 
of oral cancer. Several biomarkers have been proposed, 
but they are sometimes variable with race, lifestyle, and 
carcinogen exposure. The global knowledge of all of 
them would lead to the improvement of diagnostic and 
prognosis methods of tumor recurrence and metastasis 
to assess changes in oral lesions (3). 
-Serum biomarkers
Serum biomarkers are defined as substances changing 
quantitatively in the serum during tumor development. 
Classically, a marker is synthesized by the tumor and 
released into circulation or expressed at the cell surface 
in large quantity by malignant cells (10). These markers 
can been used in the prognosis of tumor recurrence or 
metastasis (11) because the development of the malig-
nant tumor changing their concentrations (7). The tumor 
marker/substance can be classified as tumor specific and 
tumor associated. Tumor specific substance are conside-
red as a direct result of oncogenesis, while tumor asso-
ciated marker are various proteins, enzymes, hormones 
and immunoglobulins which occur in the blood and are 
mediated by the tumor itself or by the influence of the tu-
mor on the involved tissues (12). Repeating test of serum 
biomarker allows following treatment and assessing res-
ponse to treatment, monitoring tumor progression and 
metastasis (13). However, there are not yet unified para-
meters to determinate which biomarker would be useful 
for oral cancer. 
The main focus of this systematic review is to analy-
ze the utility of serum biomarkers in the diagnosis and 
prognosis of oral cancer.
Material and Methods 
-Search Strategy and Selection criteria
A systematic, computerized database search was con-
ducted using the National Center for Biotechnolo-
gy Information (NCBI) to search MEDLINE (Pub-
med). The search was conducted using the following 
MeSHterms:”mouth neoplasms” AND marker AND 
(serum OR blood) [Mesh].
For the initial selection, article titles and/or abstracts 
were analyzed and the following inclusion criteria were 
observed: studies published in English in the last five 
years; studies of human beings; specific studies that 
analyzed a certain biomarker in serum; and study type: 
cases and controls studies, prospective and/or retrospec-
tive clinical studies. The exclusion criteria were: studies 
which do not mention the measurement method, studies 
that analyses markers in saliva.
Following initial selection, we read the previously selec-
ted articles fully, applying the selection criteria (Fig. 1) 
to determine final inclusion or exclusion from the study.
Fig. 1. Eligibility criteria for inclusion in the final review.
-Quality rating
A methodological quality rating was performed accor-
ding to the PRISMA statement criteria in order to verify 
the strength of scientific evidence in clinicaldecision-
making. The classification of the risk of bias potential 
for each study was based on the criteria adopted by 
Clementini et al. (14) described as follows: random se-
lection of the sample; definition of inclusion/exclusion 
criteria; follow-up reports; validated measurements; 
statistical analysis. A study that included all the criteria 
mentioned above was classified as having a low risk of 
bias; astudy that did not include one of these criteria was 
classified as having a moderate risk of bias; when two 
or more criteria were missing, the study was assigned a 
high risk of bias (Table 1).
Results
The electronic database search was performed on De-
cember, 2013 and yielded 130 results. Seventy articles 
were identified as relevant after reading the title and/or 
abstract. The full text of these 70 papers was evaluated 
according to the selection criteria in table 1. Of these 70 
articles, six did not fulfill one or more selection criteria 
and were excluded. Twenty-seven articles were included 
in the final review. A flowchart of the selection and eva-
luation processes is shown in figure 2.
Of the articles included in the final review, twenty-two 
were cases/controls studies, one was a cohort study, two 
were prospective, and two were retrospective. The sam-
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Year Author Random 
selection in 
population 
Defined 
inslusion/exclusion 
criteria 
Report loss 
to
follow-up 
Validated
measurements 
Statistical 
analysis 
Estimated
potential 
risk of 
bias
2014 Pajkumar, N Cases/Controls Yes No Yes Yes Moderate 
2013 Xia O-Hong, G Cases/Controls Yes No Yes Yes Moderate 
2013 Tsai, YD Prospective Yes Yes No Yes Moderate 
2013 Chang, KP Cases/Controls Yes No Yes Yes Moderate 
2013 Chang, KP Cohort study Yes No Yes Yes Moderate 
2013 Ratajczak-wana, W Cases/Controls Yes No No Yes High 
2012 Huang,SF Retrospective Yes Yes Yes Yes Low 
2012 Schiegnitz, E Cases/Controls Yes No Yes Yes Moderate 
2012 Brailo, V Cases/Controls Yes No Yes Yes Moderate 
2012 Brailo, V Cases/Controls Yes No Yes Yes Moderate 
2012 Tadbir, AA Cases/Controls Yes No Yes Yes Moderate 
2012 Cheng, SJ Cases/Controls Yes Yes Yes Yes Low 
2011 Chang,KP Cases/Controls Yes Yes Yes Yes Low 
2011 Cordella, C Retrospective Yes Yes Yes Yes Low 
2011 Prabhu, K Cases/Controls Yes Yes Yes Yes Low 
2011 Joshi, M Cases/Controls Yes No Yes Yes Moderate 
2011 Li, C Cases/Controls Yes Yes Yes Yes Low 
2011 Sawant Cases/Controls Yes Yes Yes Yes Low 
2011 Nayak, S Cases/Controls Yes No Yes Yes Moderate 
2010 Batista Faria, P Cases/Controls Yes Yes No Yes Moderate 
2010 Tu, HF Cases/Controls Yes No Yes Yes Moderate 
2010 Tamaki, S Cases/Controls Yes Yes Yes Yes Low 
2010  Feng, XY Cases/Controls Yes Yes Yes Yes Low 
2010 Harshkant, P Cases/Controls No Yes Yes Yes Moderate 
2010 Friedrich Prospective No Yes No Yes High 
2009 Khandavilli, SD Prospective Yes Yes Yes Yes Low 
2009 Liu, CJ Cases/Controls Yes Yes Yes Yes Low
Table 1. Quality assessment of the prospective and retrospective studies included.
ple size of each cases/controls study ranged from 27 to 
237 for patients and 14 to 112 for healthy controls (Table 
2).
The most used measurement method was ELISA (en-
zyme-linked immunosorbent assay) in 17 studies, whe-
reas other authors used Immunohistochemistry, Western 
Blott, flowcytometric analysis, IRMA (immunoradiome-
tric assay),Resorcinol Reagent Method, Cystein Reagent 
method, particle enhanced turbimetric assay technique 
and PCR (Polymerase Chain Reaction) (Table 2).
The twenty-six articles included in the final review re-
ported twenty-two different biomarkers used in diagno-
sis and/or prognosis of oral cancer. Of those, four were 
specific tumor markers, direct result of oncogenesis, and 
twelve were associated tumor markers, substances me-
diated by the tumor (Table 3).
Regarding the quality assessment, twelve studies achie-
ved low risk of bias. Twelve studies were determined 
moderate risk and two studies were assigned to have 
high risk of bias (Table 1).
Discussion
Biomarkers have been wide accepted in other disciplines 
but there is no consensus for their use in oral malignan-
cies. Despite recent advances in surgical, radiotherapy, 
and chemotherapy treatment protocols, the survival of 
patients with OSCC still lacks significant improvement. 
This unsatisfactory treatment may be explained by the 
fact that OSCCs frequently present with extensive local 
invasion and advanced stages (15,16). That makes ne-
cessary the development of new tools for the diagnosis 
and prognosis. 
Tumor growth, invasion and metastasis are multiple step 
processes in which many genes and molecules are in-
volved. The molecular biology of OSCC is complex and 
OSCC develops from the dysfunction of several interre-
lated pathways (17). 
Our systematic review shows how several authors in the 
last years have looked for the best marker for diagnose 
oral cancer at earlier stages, establish the prognosis and 
increase the survival of patients with this disease.
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Fig. 2. PRISMA Flow chart.
-Adiponectine
Adiponectin is an adipokine produced predominantly 
by adipocytes that circulates abundantly in plasma and 
functions as an anti-diabetic, anti-atherogenic, anti-in-
flammatory and anti-angiogenic hormone (18). 
In their study Guo et al. (19) showed that serum adipo-
nectin level was reduced in tongue squamous cell car-
cinoma (TSCC), and inversely associated with histolo-
gical grade and lymphnode metastasis of TSCC. They 
suggested that hypoadiponectinemia is correlated with 
histopathologic features of TSCC, and could be a new 
biomarker of aggressive phenotype in TSCC. But they 
still reckon the underlying mechanisms of adiponectin 
in potential cancer suppression are not fully elucidated.
-Annexin A1 mRNA
Annexin A1 an anti-inflammatory and calcium-depen-
dent protein of the superfamily of annexins, may have 
important regulatory roles in tumor development and 
progression (20). The Annexin A1 gene expression was 
investigated by Faria et al. (21), in peripheral blood sam-
ples of patients with oral squamous cell carcinoma and 
control subjects and Annexin A1 mRNA was expressed 
in all of them. Comparative analysis of OSCC blood pa-
tients showed significantly lower Annexin A1 expression 
when compared to blood sample of control individuals. 
However, there were no significant differences between 
patients’ subgroups in relation to smoking, drinking, re-
currence, TNM staging histopathological grading or the-
rapies. This present study revealed the Annexin mRNA 
as new possible transcript biomarker for early detection 
of OSCC in the peripheral blood of patients.
-Cyclin D1 
Xiao-yu Feng et al. (22) measured the level of some bio-
markers (SCCA, Cyfra 21-1, epidermal growth factor 
receptor (EGFR) and Cyclin D1) in an attempt to deter-
mine the usefulness of their combined determination in 
the diagnosis of OSCC. They concluded that Cyclin D1, 
the product of the CCND1 gene located on chromosome 
11q13, had the highest diagnostic specificity. Moreover 
the combined detection of EGFR and Cyclin D1 had the 
highest sensitivity, specificity and accuracy.
A previous study (23), demonstrates that Cyclin D1ex-
pression was significantly associated with the presence of 
occult lymph node metastases. These data suggest that the 
immunohistochemical analysis of Cyclin D1 expression in 
diagnostic biopsy samples may be an additional tool for se-
lecting patients to be treated with elective neck dissection.
-C-Reactive Protein (CRP)
CRP is a functional analogue to immunoglobulin G, 
which synthesis by pro-inflammatory cytokines. An 
increase in the value of CRP has been demonstrated in 
patients with inflammatory disease and various cancers. 
In a recent study, Khandavilli et al. (24), investigated 
the relationship between preoperative serum CRP levels, 
tumor size, stage and survival for oral cancer patients. 
They found that two years survival rates in patients with 
preoperative elevation of serum CRP, more than 5mg/L, 
was significantly less favorable (44%) than that in pa-
tients without serum CRP elevation (90%).It demonstra-
ted the link between raised CRP and malignant potential 
of oral SCC, concluding that it could be used as an inde-
pendent prognostic indicator for patients with oral SCC 
treated by primary surgery.
-Decoy receptor 3 (DcR3) 
DcR3 functions as a death decoy inhibiting apoptosis 
mediated by the tumor necrosis factor receptor family. 
Frequently, gene amplification of DcR3 has been detec-
ted in various malignant tumors. Tu et al. (25)  analyzed 
serum DcR3 level by an enzyme-linked immunosorbent 
assay (ELISA), quantitativepolymerase chain reaction 
(Q-PCR) and immunochemistry. They found that eleva-
ted serum DcR3 (>284pg/ml ) was associated with nodal 
metastasis and worse prognosis, concluding that serum 
DcR3 level is an independent prognostic factor of OSCC 
and also a predictor for neck nodal metastasis.
-Growth-differentiation factor (GDF 15)
Growth-differentiation factor 15 (GDF 15) is a member 
of the transforming growth factor-b (TGF-b) superfa-
mily, involved in tumor pathogenesis and its expression 
is increased in many types of cancers (26). Schiegnitz 
et al. (27) reported for the first time, in vivo, enhanced 
serum GDF 15 levels in patients with OSCC and pro-
vided evidence demonstrating a significant relationship 
between serum GDF 15 levels and prognosis of the pa-
tients. However, they concluded the role of GDF 15 in 
cancer pathophysiology is not clear yet.  The diagnostic 
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MARCADOR ESTUDIO DISEÑO MEDICIÓN VALOR BIOLÓGICO RELEVANCIA 
Adiponectine 
(Xia O-Hong, G; 2013)  
Cases/Controls x 59 TSCC 
 
x 50 healthy 
patients 
Immunohisto-
chemistry 
 
Western Blot 
x TSCC= 5.0±2.4µg/ml 
x Controls= 
8.4±3.5µg/ml 
Hypoadiponectinemia predict 
aggresive phenotype 
(inverselyassociated) 
Annexin A1 mRNA 
(Batista Faria, P; 2010)  
Cases/Controls x 27 OSCC 
x 25 healthy 
patients 
Q.R.time PCR Lowerexpression Decrease associated with 
cancerous phenotype 
(Tumor suppressor gene) 
 
CRP + SCC-Ag 
(Huang,SF ; 2012)  
Retrospective 
(preoperative serum) 
x 142 OSCC ELISA x Cut-off SCC-Ag  2.0 
ng/ml 
x Cut-off CRP  5.0 
ng/ml 
Indicates overall survival 
CRP (Khandavilli,SD; 2009)  Prospective x 60 OSCC 
Preoperative serum 
Particle 
enhanced 
turbimetric 
immunoassayte
chnique 
x Ranged= 0.1-89.3 
mg/L 
x 0-5 mg/L=normal 
x >5 mg/L=raised 
(T3,T4) 
Indicates overall survival 
Citokine markers (Chang,KP; 
2011)  
Cases/Controls (48 
proteins) 
x 111 OSCC 
x 112 healthy 
patients 
x 107 premalignant 
lesions 
ELISA x OSCC 12 proteins 
dysregulated 
VEGF >4.87 pg/ml= worse 
prognosis OSCC 
CXCL-9 
(Chang, KP; 2013)  
Cases/Controls x 181 OSCC 
x 231 healthy 
patients 
ELISA x CXCL-9 > 209 pg/ml  Worse prognosis 
DCR3 
 (Tu, HF; 2010)  
Prospective 
(preoperative DCR3 
level) 
x 148 OSCC ELISA 
QPCR 
Immunohistoch
emistry 
 
Follow-up 23±11.8 
months 
>284 pg/ml= worse 
prognosis 
(nodal metastasis) 
Predictor of survival 
GDF 15 
(Schiegnitz, E; 2012)  
Cases/Controls 
 
x 64 OSCC 
x 30healthy patients 
ELISA 
 
x OSCC preoperative= 
1545±774pg/ml 
x OSCC postoperative= 
953±438 pg/ml 
GDF15 serum level <875 pg/ml 
=higher survival 
 
Preoperative Hemoglobine 
(Cordella, C; 2011)  
Retrospective 
(follow-up 12 months) 
287 OSCC Hb 71,4% normal Hb 18.5% 
mild anemia 
10.1% severe anemia 
Anemia significant for the 
development of lymph node 
metastasis 
<11g/dl poor prognosis 
TNFĮ 
(Brailo, V; 2012)  
Cases/Controls 
 
x 28 OSCC 
x 29 leucoplakia 
x 31healthy patients 
ELISA x OSCC=5±2.51 pg/ml 
x Leucoplakia=6±1.06 
pg/ml 
x Controls=8±1.34pg/m
l (p=0.038) 
 
TNFĮ > in control serum 
 
IL6 (Brailo, V; 2012)  Cases/Controls x 28 OSCC 
x 29 leucoplakia 
x 31 healthy patients 
ELISA x OSCC=3±O.58 pg/ml 
x Leucoplakia=4±1.22 
pg/ml 
x Controls=3±23pg/Iml 
(p=0.989) 
 
 
IL6 (Chang, KP; 2013)  Cohort study x 237 OSCC 
x 104 premalignant 
lesions 
x 125 healthy 
patients 
ELISA x T1= 0.0 pg/ml 
x T2= 0.0 pg/ml 
x T3=1.3 pg/ml 
x T4= 5.0 pg/ml 
(p= 1.35) 
Independent prognosis factor for 
overall survival 
MiCB 
(Tamaki, S; 2010)  
Cases/Controls x 60 OSCC 
x 50healthy patients 
ELISA x Controls=21.2±16.1 
pg/ml 
x T1= 
12.4±16.2pg/ml21.7±
10.5pg/ml 
x T2=  
x T3= 30.1±17.2pg/ml 
x T4= 37.8±10.1pg/ml 
sMICBlevels 
significantly increased in stage IV 
OSCC . 
Associated with decreased 
survival rates i 
MMP-3 
(Tadbir, AA; 2012)  
Cases/Controls x 40 OSCC 
x 45 healthy patients 
ELISA x OSCC= 9.45±4.6 
ng/dl 
x Control= 5.9±3.6 
ng/dl 
Helpful for diagnosis 
 (not correlated to clinical stages)  
MMP-9 
(Liu, CJ; 2009)  
Cases/Controls x 161 patients ELISA x LN(+)=290.22±28.44 
ng/dl 
x LN(-)= 180±15.09 
MMP-9> 226.7 ng/ml= shorter 
overall survival 
Table 2. Summarize evidence on selected papers.
utility of GDF 15 could be improved by combining GDF 
15 with other serum markers.
-Hemoglobine (Hb)
Low Hb levels are indeed associated with poor tumor 
oxygenation and increasing Hb concentrations are co-
rrelated with higher pO2 levels and lower hypoxic tissue 
fractions. In a retrospective study, Cordella et al. (28) 
settled the hyphotesis that if a low Hb concentration is a 
predictor of decreased local control, Hb corrections may 
significantly improve tumor oxygenation and prognosis. 
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ng/dl 
Nitric Oxide (Ratajczak-wrona, 
W; 2013)  
Cases/Controls x 24 OSCC 
x 15 healthy patients 
ELISA x Higher in stage IV Nitric Oxide concentration 
correlated with stage 
VEGF 
(Liu, CJ; 2009)  
Cases/Controls x 161 patients ELISA Cut off=497.04 pg/ml VEGF >497.04 pg/ml 
Shorter overall survival 
Phosphodiesterase (Prabhu, K; 
2011)  
Cases/Controls x 39 OSCC 
x 20 healthy patients 
ELISA x OSCC= 63.3µmol/ml 
x Controls= 12µmol/ml 
PDE levels increased in OSCC. 
Correleatedqith advanced stage of 
cancer. 
Placenta Growth Factor 
(Cheng, SJ;2012)  
Cases/Controls x 72 OSCC 
(before/after 
surgery) 
x 30 healthy patients 
ELISA x OSCC Presurgery= 
19.1±19.7 pg/ml 
x OSCC
Postsurgery=11.0±6.6 
pg/ml 
x Controls= 10.1±4.5 
pg/ml 
Shows prognosis, recurrence. 
SCCAg
(Feng; 2010)  
Cases/Controls x 70 OSCC
x 72 healthy patients 
ELISA Cut off= 1.5 ng/ml Decrease after surgery 
VEGF 
(Feng; 2010)  
Cases/Controls x 70 OSCC
x 72 healthy patients 
ELISA Cut off= 1.7 ng/ml >specificity 
Cycling D1 
(Feng; 2010)  
Cases/Controls x 70 OSCC
x 72 healthy patients 
ELISA Cut off=1.7 ng/ml >sensitivity 
>accuracy 
Serum fucose 
(Pajkumar, N; 2011)  
Cases/Controls x 53 OSCC
x 14 healthy patients 
Cystein Reagent 
(Winzler) 
x OSCC= 15.34±0.86 
mg% 
x Controls=5.323±6.767 
mg% 
Serum Leptin 
(Harshkant, P;2010)  
Cases/Controls x 31 OSCC
x 28 health ypatients 
ELISA x OSCC= 2.76 ± 1.98 
ng ⁄ ml  
x Controls = 5.71 ± 3.58 
ng ⁄ ml  
Serum leptin could provide state 
of cachexia in OSCC PATIENTS 
Sialic acid levels  
(Joshi, M; 2011)  
Cases/Controls x 30 OSCC
x 30oral precancer 
x 30 healthy patients 
Resorcinol 
Reagent
Method 
x  OSCC= 
84.44±8.26mg/dl 
x Precancer = 
66.95±4.61mg/dl  
x Control group = 
58.59±5.81mg/dl 
Th17 cells 
(Li, C; 2011)  
Cases/Controls x 67 HNSCC  
x 21 healthy patients 
Flow cytometric 
analysis 
ELISA 
HNSCC= 1.0±0.4% 
LN (+)= 1.4±0.6% 
LN(-)= 0.7±O.3% 
Controls= 0.3±0.1% 
TH17 cells proportion increases 
in advanced HNSCC 
TPA 
(Sawant, SS; 2011)  
Cases/Controls x 80 OSCC
x 24 healthy patients 
IRMA Cut off= 140.93 U/L Prediction of recurrence 
VEGF-A 
(Nayak, S; 2011)  
Cases/Controls x 60 OSCC
x 60 oral precancer 
x 20 healthy patients 
ELISA 
PCR
x OSCC=
1264.08±1216.70 
pg/ml 
x Precancer = 
462.54±322.76 pg/ml 
x Control group = 
187.91±106.75 pg/ml 
VEGF level upregulated in OSCC 
VEGF 
(Friedrich; 2010)  
Cases/Controls x 86 OSCC patients ELISA High variability.  No correlation with clinical 
stages
Visfatin/pre-b cell colony 
enhancing factor (Tsai, YD; 
2013)  
Cases/Controls x 51 OSCC
x 57 healthy patients 
ELISA x OSCC= 7.0±4.5 ng/ml 
Control= 4.8±1.9 ng/ml 
Significant correlation with white 
blood cell count 
Table 2. (continue) Summarize evidence on selected papers.
They found that anemia was significant for the develo-
pment of lymph node metastasis as well as for the de-
velopment of local recurrence. Preoperative transfusion 
or erythropoietin administration before surgery has very 
important economic as well as physiologic consequen-
ces so this idea should be considered with caution. 
Further investigations are needed in a prospective set-
ting, with greater evidence, to rule out dependency with 
other more important factors. 
-Cytokines
Proinflammatory cytokines interleukin 1 beta (IL-1β), 
interleukin 6 (IL-6) and tumor necrosis factor alpha 
(TNF-α) regulates inflammatory response and play sig-
nificant role in the development of cancer (29).
J Clin Exp Dent-AHEAD OF PRINT                                                                                                                                                                                                         Serum biomarkers
E7

1. Adiponectine Adiponectin is an adipokine produced predominantly by 
Adipocytes. It functions as an anti-diabetic, anti-
atherogenic, anti-inflammatory and anti-angiogenic 
hormone.
Associated biomarker 
2. Annexin A1 mRNA 
 
Annexin A1 ,an anti-inflammatory and calcium-dependent 
protein of the superfamily of annexins, may have important 
regulatory roles in tumor development and progression 
Associated biomarker 
3. CRP C-Reactive Protein (CRP)is a functional analogue to 
immunoglobulin G, which synthesis by pro-inflammatory 
cytokines 
Associated biomarker 
4. Cycling D1 Cyclin D1, the product of the CCND1 gene located on 
chromosome 11q13 
Associated biomarker 
5. DCR3 
 
Decoy receptor 3. DcR3 functions as a death decoy 
inhibiting apoptosis mediated by the tumor necrosis factor 
receptor family. 
Specific biomarker 
6. GDF 15 Growth-differentiation factor 15 (GDF 15) is involved in 
tumor pathogenesis. Its expression is increased in many 
types of cancers. (associated biomarker) 
Specific biomarker 
7. Hb Hemoglobine level mediates tumor response to radiation 
through the delivery of oxygen tothe tumor. 
Associated biomarker 
8. TNFĮ Tumor necrosis factor-alpha Specific biomarker 
9. IL6  Interleukin 6. Proinflammatory cytokines  Associated biomarker 
10. MiCB Major histocompatibility complex class I-related chain A/B 
(MICA/B), a ligand of natural killer group 2D (NKG2D) 
immunoreceptors. 
11. MMP-3 Matrix metalloproteinase-3 is a member of MMP family 
which is capable to degrade a broad range of substrates. 
MMP-3 reveals pathological expression in many tumors. 
Associated biomarker 
12. MMP-9 Matrix metalloproteinase-9. Potent factors involved in 
angiogenesis. Under physiological conditions MMP are 
capable of degrading extracellular matrix and basement 
membrane components. 
Associated biomarker 
13. Nitric Oxide  Nitric Oxide concentration plays an essential role in the 
process of lipid peroxidation. 
Associated biomarker 
14. PDEs Phosphodiesterases have a fundamental role in the 
transduction of the intracellular signals and tumor growth 
by influencing angiogenesis. 
Associated biomarker 
15. PlGF Placenta growth factor is a member of the vascular 
endothelial growth factor (VEGF) family.PlGF stimulates 
proliferation, differentiation, and survival of endothelial 
cells. 
Associated biomarker 
16. SCCAg 
 
Squamous cell carcinoma antigen. A tumor-associated 
protein,  
an adjunct in the diagnosis of the disease (associated 
biomarker) 
Specific biomarker 
17. Serum fucose L-fucose, is a monosaccharides that compounds serum 
glycoproteins. 
Associated biomarker 
18. Serum Leptin Leptin is a protein of cytokine family, related to body 
weight, metabolism and reproductive function 
Associated biomarker 
19. Sialic acid levels 
 
Siacilic acids are acetylated derivatives of neuramic acid. 
They are attached to the non-reduced residue of 
carbohydrate chains of glycoproteins and glycolipids. 
Associated biomarker 
20. Th17 cells 
 
TH17 cells are the third subset of CD4+ T helper cells (T 
lymphocytes that belong to the CD4+ subset). Important 
role in inflammation. 
Associated biomarker 
21. TPA Tissue polypeptide Antigen. 
TPA is one of the most frequently used cytokine evaluated 
as a serum marker 
Associated biomarker 
22. VEGF Vascular endothelial growth factor. 
VEGF is a multifunctional cytokine that plays a pivotal role 
in angiogenesis. (induction of angiogenesis in tumour 
growth)
Associated biomarker 
23. Visfatin/pre-b cell 
colony enhancing 
factor  
Nicotiamidephosphoribosyltransferase or pre-B cell colony 
enhancing factor, is a pro-inflammatory cytokine.It 
regulates growth, apoptosis, and angiogenesis. 
Associated biomarker 
Table 3. Biomarkers identified in studies. 
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In their study, Brailo et al. (30) showed that patients with 
oral cancer have higher salivary IL-1β and IL-6 con-
centrations compared to patients with leukoplakia and 
healthy con-trol but no significant differences in serum 
IL-6 were observed between the groups. However, serum 
TNF-α concentration was significantly higher in control 
subjects compared to oral cancer patients.
Chang et al. (16) conducted a study to demonstrate the 
possible biologic relevance of potential cytokine mar-
kers in OSCC. They analyzed the associations between 
the clinicopathologic manifestations of OSCC and the 
blood levels of the 12 individual cytokines. As Brailo et 
al. (30) did before, they find strong associations between 
some increased cytokine levels and clinical factors but 
the study did not reveal any associations between others 
cytokines with elevated levels in OSCC patients and cli-
nicopathologic manifestations.
These investigations fails to identify certain cytokines 
or cytokine panels that could be used to effectively de-
tect OSCC patients, Results from this studies and hete-
rogeneous literature data indicate that altered cytokine 
production and responsiveness in oral cancer takes place 
primarily in the oral cavity and does not reflect on serum 
cytokine concentrations
-Major complex class I-related chain A/B (MIC-B)
Expression of MIC-A/B, ligands of natural killer group 
2D, has been proposed to play an important role in tu-
mor immunosurveillance. Soluble forms of MICA/B are 
increased in sera of cancer patients and are postulated to 
impair antitumor immune response by down regulating 
expression of NKG2D immunoreceptors. In advanced 
stages of some tumors have been reported increases in 
soluble MIC-A (31). Watson et al. (31) found that OSCC 
patients with high soluble MIC-B levels had signifi-
cantly lower survival rates. Furthermore, patients with 
both high soluble MIC-A and soluble MIC-B levels also 
had markedly decreased survival rates. 
Tamaki et al. (32) reported that serum MICB levels did 
not differ significantly from those in normal control in-
dividuals. However, they indicated that serum MICB le-
vels were significantly increased in stage IV OSCC and 
it was significantly associated with decreased survival 
rates in patients. These findings suggest the utility of 
sMICB levels as a marker for tumor progression.
-Matrix metalloproteinase enzymes (MMPs)
MMPs are proteolytic enzymes and in cancer they regu-
late various cell behaviors by degradation of proteins. 
These include cancer cell growth, differentiation, apop-
tosis, migration, invasion and regulation of tumor angio-
genesis and immune surveillance. 
Liu et al. (33) analyzed the association between pre-
treatment serum levels of MMP-9 and clinic-patholo-
gical parameters and outcome for patients with OSCC. 
In this investigation patients with MMP-9 serum levels 
higher than median (226.7 ng/mL) had significantly 
shorter overall survival than those with levels lower 
than median. It suggested pretreatment serum levels of 
MMP-9 as a powerful prognostic marker in patients with 
oral squamous cell carcinoma.
Tadbir et al. (34), analysed serum MMP-3 level in OSCC 
patients. Their results showed that serum MMP-3 level 
in OSCC patients was significantly higher than healthy 
controls but they couldn`t correlate serum MMP-3 con-
centration with the clinicopathological. Unlike the pre-
viously mentioned study, the results suggest that the 
measurement of serum MMP-3 concentration might be 
helpful to diagnose OSCC but not to predict prognosis.
-Squamous cell carcinoma antigen (SCC-Ag)
SCC-Ag, a tumor-associated protein, was first isolated as 
“TA-4” from SCC tissue of the uterine cervix in 1977 (35). 
Since then, several studies have shown that serum SCCA 
was elevated in OSCC patients and could be used as an ad-
junct in the diagnosis of the disease. Recently some studies 
have found that serum SCC-Ag concentrations were signi-
ficantly increased in OSCC patients, and that the SCC-Ag 
level decreased significantly after tumor resection (22).  
SCC-Ag serum level was also correlated with tumor. 
Moreover other investigations mentioned it may be a 
useful tool for monitoring the course of the disease and 
its recurrence (22).
These studies shows evidence enough to remark the uti-
lity of SCC-Ag, a specific antigen, in the diagnosis and 
prognosis of oral cancer if serum levels are well contro-
lled during preoperative and the follow-up.
-Sialic acid level
Siacilic acids are acetylated derivatives of neuramic 
acid. They are attached to the non-reduced residue of 
carbohydrate chains of glycoproteins and glycolipids. 
Altered glycosylation of glycoconjugates is among the 
important molecular changes that accompany malignant 
transformation (35) .
Joshi (12) found the mean serum total sialic acid le-
vels in control group (58.59±5.81mg/dl), oral precancer 
(66.95±4.61mg/dl) and oral cancer group (84.44±8.26mg/
dl) were statistically significant (p<0,005). These diffe-
rences were also found by Rapjura et al. (36) (control 
group=30.25±2.49mg/dl; cancer group=63.70±19.40 mg/
dl). Sialic acid level is directly proportional to tumor bur-
den (35,36). Joshi (12) found the mean serum total sia-
lic acid levels in stage I was 71,24 mg/dl whereas it was 
73,36 ±4,65 mg/dl, 84,61±6,40 mg/dl, and 89,34± 4,68 
mg/dl in stage II, stage III and stage IV respectively.
-T(h)17
TH17 cells are the third subset of CD4+ T helper cells (T 
lymphocytes that belong to the CD4+ subset), which are 
characterized by their production of interleukin (IL).
17A and IL-17F have been verified to play an important 
role in inflammation, autoimmune diseases, and human 
organ transplantation rejection. Li et al. (37), reported an 
increase of serum IL-17 levels in patients with head and 
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neck squamous cell carcinomas (HNSCC) compared 
with healthy control subjects (123.35-45.13 pg/mL vs. 
20.78-3.95 pg/mL; p<0.05). The results indicated that 
IL-17 expression can be detected in the very early sta-
ge of squamous cell carcinoma and increases gradually 
with the development of the tumor. There was significant 
difference between TH17 cell proportions in peripheral 
blood in patients with or without lymph node metastasis. 
This study suggested that TH17 cells may be involved in 
tumor growth and metastasis of HNSCC.
-Tissue polypeptide Antigen (TPA)
TPA is one of the most frequently used cytokine evalua-
ted as a serum marker for its clinical applications.  In 
their study Sawant et al. (38), using immunoradimetric 
assay, found  that elevated levels of TPA was correlated 
significantly with stage (p = 0.02), development of recu-
rrence (p < 0.006), and impacted survival (p < 0.033). 
This result indicates that TPA can be a useful tumor mar-
ker for the prediction of recurrence and poor prognosis 
in human oral cancer.  
-Vascular endothelial growth factor (VEGF) 
VEGF is multifunctional cytokine that plays a pivotal 
role in angiogenesis. It has been considered as the most 
potent one for the induction of angiogenesis in tumor 
growth. Shang et al. (39), determinate that serum VEGF 
concentration was increased in patients with OSCC (Con-
trol group=148.80±64.17pg/ml, Cancer=567.97±338.17 
pg/ml. P<0.001) Increased values of VEGF has been 
found with progression of disease and decreased values 
after surgery. Higher level of serum VEGF was closely 
associated with lymph node metastasis 33 and clinical 
stage in OSCC patients (33,39). Finally, elevated serum 
VEGF levels have been correlated with poor disease-
free survival and poor progression-free survival in can-
cer patients (33).
We have found quite homogeneous criteria and protocol to 
investigate the role of serum biomarkers but there is still no 
unified criteria for using a certain marker or another.
Our results highlight that a wide variety of biomarkers 
have been studies and a great part of theme have demons-
trated their effectiveness in the diagnosis and/or prognosis 
of oral cancer. Most of the investigations are cases and 
controls studies where the measurement chosen system is 
ELISA. Surprisingly, the quality of the articles included 
was acceptable and were classified as “low risk of bias”.
The main limitation of the studies in our systematic re-
view is that there is no a real follow-up of the patients 
and they do not repeat all the measurements in serum. 
We think this is crucial to correlate biological values 
with the progression and prognosis of the disease so fu-
ture investigations should contemplate this item to pro-
vide more evidence of the utility of serum biomarkers.
Biomarker use for diagnosis and prognosis is supported 
by clinical and scientific evidence is relevant. Never-
theless, after selecting a certain biomarker, monitoring 
protocols should be established in oral and maxillofacial 
surgeons teams so as we have a correct understanding of 
biological values.
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